Compare JPMorgan Equity Premium Income ETF (JEPI) vs Novo Nordisk A/S (NVO) Price & Performance

JPMorgan Equity Premium Income ETFTrade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

JPMorgan Equity Premium Income ETF vs Novo Nordisk A/S — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.62, while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S pays a 3.63% dividend while JPMorgan Equity Premium Income ETF pays none. Which is the better fit depends on your goals.

	JEPI	NVO
Sector	Income / Options Overlay	Health
52-Week High	$59.88	$71.70
52-Week Low	$55.29	$35.29
Market Cap	—	$220.53B
Enterprise Value	—	$239.49B
Dividend Yield	—	3.63%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Equity Premium Income ETF

JEPI trades at $56.39, down 0.28% on the day, with technical indicators showing a bearish trend from moving averages while oscillators remain neutral. The ETF's covered call strategy generates high income but has underperformed the S&P 500 due to sector underweighting and upside caps. Recent news highlights tax inefficiencies and competition from alternatives like SPYI and DIVO.

JEPI's 8% yield appeals to income-focused investors, but total return potential is limited in bull markets. Risks include tracking error, tax disadvantages in taxable accounts, and sector concentration. Analyst sentiment is mixed, with some favoring more dynamic covered-call ETFs for better risk-adjusted returns in current market conditions.

Novo Nordisk A/S

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

JEPI

RYLD ETF's covered call strategy limits small-cap gains compared to direct Russell 2000 ETFs.24/7 Wall Street · 3 days agoBearish JPMorgan Equity Premium ETF underperforms S&P 500 and peers due to sector weight and strategy issues.Seeking Alpha · 4 days agoBearish View details →

NVO

Novo Nordisk sues Eli Lilly over misleading GLP-1 drug ads claiming superior weight-loss results.Proactive Investors · 9 hours agoBearish Novo Nordisk sues Eli Lilly over misleading ads on obesity and diabetes drug efficacy.CNBC · 12 hours agoBearish Novo Nordisk shares jump 27% on strong sales of oral Wegovy and market expansion.Seeking Alpha · 1 day agoBullish View details →

About JPMorgan Equity Premium Income ETF

JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.